Genmab-Lundbeck collaboration reaches third pre-clinical milestone
The deal allows Genmab, which received €7.5m upfront payment previously, to develop human antibodies against three central nervous system targets identified by Lundbeck. Lundbeck, which will entirely fund
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.